EGFR and non-small cell lung carcinoma: This study provides evidence that targeting the AURKA signaling pathway by alisertib may be a novel approach for overcoming EGFR-TKI resistance and for the treatment of metastatic EGFR-TKIs in NSCLC patients [52].